Data from several observational studies suggest that discontinuation of TNFi after achieving either remission or low disease activity results in relapses in 60-74% of patients, occasionally within a few weeks to months from discontinuation (see Supplementary Appendix 6, available at http://onlin elibr ary. wiley.com/doi/10.1002/art.41042/ abstract Tapering of TNFi could entail a change in either the dose or frequency of administration. Two controlled unblinded trials of tapering etanercept to